These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22836064)

  • 1. From the editor: what are the important questions for clinical trials?
    Brown WV
    J Clin Lipidol; 2012; 6(4):299-300. PubMed ID: 22836064
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 3. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol].
    Carlson LA
    Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials and tribulations. Cholesterol veers off script.
    Couzin J
    Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
    [No Abstract]   [Full Text] [Related]  

  • 5. [Statins, life style and treatment of hypercholesterolemia: the time is changing, criteria too].
    Pintó X
    Med Clin (Barc); 2006 Feb; 126(6):217-9. PubMed ID: 16510095
    [No Abstract]   [Full Text] [Related]  

  • 6. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 7. High blood cholesterol.
    National Heart, Lung and Blood Institute
    Nutr Clin Care; 2003; 6(3):108-14. PubMed ID: 14979453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy and clinical trials.
    Duttaroy AK; Ray TK
    Curr Opin Lipidol; 2008 Jun; 19(3):330-2. PubMed ID: 18460929
    [No Abstract]   [Full Text] [Related]  

  • 10. Goals for cholesterol lowering.
    Stankler L
    Circulation; 1999 May; 99(18):2477. PubMed ID: 10318741
    [No Abstract]   [Full Text] [Related]  

  • 11. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously].
    MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253
    [No Abstract]   [Full Text] [Related]  

  • 13. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
    Rudling M
    Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-HDL-cholesterol reduction: the challenges of applying clinical trial results in the real world.
    De Geest B; Van Linthout S
    Eur Heart J; 2024 Oct; 45(39):4216-4218. PubMed ID: 39217498
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 17. Intervening on HDL-C: is it possible? Does it work?
    Wierzbicki AS
    Int J Clin Pract; 2007 Nov; 61(11):1782-6. PubMed ID: 17935541
    [No Abstract]   [Full Text] [Related]  

  • 18. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.